https://m2.mtmt.hu/ hun 2026-09-21 03:17 JournalArticle 33564736 VALIDATED true National Institute of Mental Health, Neurology and Neurosurgery, Budapest, 1145, Hungary Scanomed Ltd, Budapest, 1145, Hungary Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, 1085, Hungary National Cancer Registry, National Institute of Oncology, Budapest, 1122, Hungary Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, 1091, Hungary PET/CT Outpatient Department, National Institute of Oncology, Budapest, 1122, Hungary Export Date: 1 June 2023 Correspondence Address: Kenessey, I.; National Cancer Registry, Hungary; email: kenessey.istvan@oncol.hu 0 false 2026-07-15T11:08:31.652+0000 2024-04-17T08:09:27.378+0000 2023-01-16T07:24:14.383+0000 true 10070075 Nádas Orsolya /api/admin/10070075 Admin Nádas Orsolya (OOI admin4) true 2025-01-16T09:40:34.753+0000 2023-02-08T12:41:07.835+0000 true 10080205 Szalóky-Siki Ágnes /api/admin/10080205 Admin Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Nagy, Dávid Gergő true true /api/journal/10056704 REVIEWED BIOMEDICINES 2227-9059 true false 10056704 false 10056704 true 2227-9059 Journal FOREIGN 11 1 128 128 13 2023 Primary malignant brain tumors are heterogeneous and infrequent neoplasms. Their classification, therapeutic regimen and prognosis have undergone significant development requiring the innovation of an imaging diagnostic. The performance of enhanced magnetic resonance imaging depends on blood–brain barrier function. Several studies have demonstrated the advantages of static and dynamic amino acid PET/CT providing accurate metabolic status in the neurooncological setting. The aim of our single-center retrospective study was to test the primary diagnostic role of amino acid PET/CT compared to enhanced MRI. Emphasis was placed on cases prior to intervention, therefore, a certain natural bias was inevitable. In our analysis for newly found brain tumors 18F-FET PET/CT outperformed contrast MRI and PWI in terms of sensitivity and negative predictive value (100% vs. 52.9% and 36.36%; 100% vs. 38.46% and 41.67%), in terms of positive predictive value their performance was roughly the same (84.21 % vs. 90% and 100%), whereas regarding specificity contrast MRI and PWI were superior (40% vs. 83.33% and 100%). Based on these results the superiority of 18F-FET PET/CT seems to present incremental value during the initial diagnosis. In the case of non-enhancing tumors, it should always be suggested as a therapy-determining test. true INTERNATIONAL 2023 true true true false true false GOLD 2026-07-15 true https://doi.org/10.3390/biomedicines11010128 6 0 6 3 2 4 5 5 6 6 6 3 3 3 3 0 6 3 6 3 0 4 4 Folyóiratcikk Journal Article 24 6 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2023 0 2 0 2 0 2024 0 0 0 0 0 2025 0 3 2 3 2 2026 0 1 1 1 1 Q1 false 10002526 false false false 2023-02-07T12:41:07.570+0000 Amerikai úti Ideggyógyászati és Idegsebészeti I... (OMIII); Országos Mentális, Ideggyógyászati és Idegsebés...; Országos Onkológiai Intézet; Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I); Patológiai, Igazságügyi és Biztosítási Orvostan... (SE / AOK / I) 8 39 5 9 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 106310840 /api/authorship/106310840 Nagy, Dávid Gergő [Nagy, Dávid Gergő (idegsebészet, neu...), szerző] Országos Mentális, Ideggyógyászati és Idegsebés...; Amerikai úti Ideggyógyászati és Idegsebészeti I... (OMIII) 1 0.111 true false false Author 10083677 /api/author/10083677 Nagy Dávid Gergő (idegsebészet, neuroonkológia) Nagy Dávid Gergő true true Nagy Dávid Gergő true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310841 /api/authorship/106310841 Fedorcsák, Imre [Fedorcsák, Imre (idegsebészet), szerző] Országos Mentális, Ideggyógyászati és Idegsebés... 2 0.111 false false false Author 10045848 /api/author/10045848 Fedorcsák Imre (idegsebészet) Fedorcsák Imre true 10045848 true Fedorcsák Imre true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310842 /api/authorship/106310842 Bagó, Attila György [Bagó, Attila György (Idegsebészet), szerző] Országos Mentális, Ideggyógyászati és Idegsebés... 3 0.111 false false false Author 10026954 /api/author/10026954 Bagó Attila György (Idegsebészet) Bagó Attila György true 10026954 true Bagó Attila György true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310843 /api/authorship/106310843 Gáti, Georgina [Gáti, Georgina (neurobiológia), szerző] Országos Mentális, Ideggyógyászati és Idegsebés... 4 0.111 false false false Author 10032350 /api/author/10032350 Gáti Georgina (neurobiológia) Gáti Georgina true 10032350 true Gáti Georgina true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310844 /api/authorship/106310844 Martos, János [Martos, János (Radiológia, neuro...), szerző] Országos Mentális, Ideggyógyászati és Idegsebés... 5 0.111 false false false Author 10030006 /api/author/10030006 Martos János (Radiológia, neuroradiológia) Martos János true 10030006 true Martos János true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310845 /api/authorship/106310845 Szabó, Péter 6 0.11111111 false false false Szabó Péter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310846 /api/authorship/106310846 Rajnai, Hajnalka [Rajnai, Hajnalka (Patológia), szerző] Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 7 0.111 false false false Author 10028430 /api/author/10028430 Rajnai Hajnalka (Patológia) Rajnai Hajnalka true 10028430 true Rajnai Hajnalka true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310847 /api/authorship/106310847 Kenessey, István** ✉ [Kenessey, István (Patológia, onkológia), szerző] Országos Onkológiai Intézet; Patológiai, Igazságügyi és Biztosítási Orvostan... (SE / AOK / I) 8 0.111 false true true Author 10017547 /api/author/10017547 Kenessey István (Patológia, onkológia) Kenessey István true 10017547 true Kenessey István true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 106310848 /api/authorship/106310848 Borbély, Katalin [Borbély, Katalin (Neurológia, nukle...), szerző] Országos Onkológiai Intézet 9 0.111 false true false Author 10002526 /api/author/10002526 Borbély Katalin (Neurológia, nukleáris medicina) Borbély Katalin true 10002526 true Borbély Katalin true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 22846576 /api/publicationidentifier/22846576 DOI: 10.3390/biomedicines11010128 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.3390/biomedicines11010128 https://doi.org/10.3390/biomedicines11010128 false true PublicationIdentifier 23114400 /api/publicationidentifier/23114400 WoS: 000914427600001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000914427600001 https://www.webofscience.com/wos/woscc/full-record/000914427600001 true true PublicationIdentifier 23046681 /api/publicationidentifier/23046681 Scopus: 85146705622 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85146705622 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85146705622 false true PublicationIdentifier 22915411 /api/publicationidentifier/22915411 PubMed: 36672636 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 36672636 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36672636&dopt=Abstract true true SjrRating 11358265 /api/sjrrating/11358265 sjr:Q1 (2023) Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous) BIOMEDICINES 2227-9059 75 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1301 /api/classificationexternal/1301 Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous) true 1301 true Q1 DIRECT true true Reference 37391799 /api/reference/37391799 1. Globocan (2022, September 15). Cancer Today. Available online: https://gco.iarc.fr. 1 false true Reference 37391800 /api/reference/37391800 2. Stupp 2005: Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma., N. Engl. J. Med., 352, p. 987, DOI: 10.1056/NEJMoa043330 2 10.1056/NEJMoa043330 false true Reference 37391801 /api/reference/37391801 3. Weller 2017: Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial., Lancet Oncol., 18, p. 1373, DOI: 10.1016/S1470-2045(17)30517-X 3 10.1016/S1470-2045(17)30517-X false true Reference 37391802 /api/reference/37391802 4. Richardson 2020: Overcoming the Odds: Toward a Molecular Profile of Long-Term Survival in Glioblastoma., J. Neuropathol. Exp. Neurol., 79, p. 1031, DOI: 10.1093/jnen/nlaa102 4 10.1093/jnen/nlaa102 false true Reference 37391803 /api/reference/37391803 5. Louis 2021: The 2021 WHO Classification of Tumors of the Central Nervous System: A summary., Neuro-Oncology, 23, p. 1231, DOI: 10.1093/neuonc/noab106 5 10.1093/neuonc/noab106 false true Reference 37391804 /api/reference/37391804 6. Weller 2020: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood., Nat. Rev. Clin. Oncol., 18, p. 170, DOI: 10.1038/s41571-020-00447-z 6 10.1038/s41571-020-00447-z false true Reference 37391805 /api/reference/37391805 7. Bent 2021: Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): Second interim analysis of a randomised, open-label, phase 3 study., Lancet Oncol., 22, p. 813, DOI: 10.1016/S1470-2045(21)00090-5 7 10.1016/S1470-2045(21)00090-5 false true Reference 37391806 /api/reference/37391806 8. Andronesi 2018: Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate., Nat. Commun., 9, p. 1474, DOI: 10.1038/s41467-018-03905-6 8 10.1038/s41467-018-03905-6 false true Reference 37391807 /api/reference/37391807 9. Ginsberg 1998: The Significance of Lack of MR Contrast Enhancement of Supratentorial Brain Tumors in Adults: Histopathological Evaluation of a Series., Surg. Neurol., 49, p. 436, DOI: 10.1016/S0090-3019(97)00360-1 9 10.1016/S0090-3019(97)00360-1 false true Reference 37391808 /api/reference/37391808 10. Scott 2002: How often are nonenhancing supratentorial gliomas malignant? A population study., Neurology, 59, p. 947, DOI: 10.1212/WNL.59.6.947 10 10.1212/WNL.59.6.947 false true Reference 37391809 /api/reference/37391809 11. Ericson 2006: Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas., J. Neurol. Sci., 246, p. 85, DOI: 10.1016/j.jns.2006.02.015 11 10.1016/j.jns.2006.02.015 false true Reference 37391810 /api/reference/37391810 12. Wintermark 2010: The pre-requisite of a second-generation glioma PET biomarker., J. Neurol. Sci., 298, p. 11, DOI: 10.1016/j.jns.2010.07.024 12 10.1016/j.jns.2010.07.024 false true Reference 37391811 /api/reference/37391811 13. Nyary 2008: FDG, MET or CHO? The quest for the optimal PET tracer for glioma imaging continues., Nat. Clin. Pract. Cardiovasc. Med., 4, p. 470, DOI: 10.1038/ncpneuro0863 13 10.1038/ncpneuro0863 false true Reference 37391812 /api/reference/37391812 14. Heiss 1999: Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo., J. Nucl. Med., 40, p. 1367 14 false true Reference 37391813 /api/reference/37391813 15. Dunet 2012: Performance of 18F-Fluoro-Ethyl-Tyrosine (18F-FET) PET for the Differential Diagnosis of Primary Brain Tumor: A Systematic Review and Metaanalysis., J. Nucl. Med., 53, p. 207, DOI: 10.2967/jnumed.111.096859 15 10.2967/jnumed.111.096859 false true Reference 37391814 /api/reference/37391814 16. Stegmayr 2019: O-(2-[18F]-Fluoroethyl)-L-Tyrosine (FET) in Neurooncology: A Review of Experimental Results., Curr. Radiopharm., 12, p. 201, DOI: 10.2174/1874471012666190111111046 16 10.2174/1874471012666190111111046 false true Reference 37391815 /api/reference/37391815 17. Lohmann 2019: FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma., Eur. J. Nucl. Med., 46, p. 591, DOI: 10.1007/s00259-018-4188-8 17 10.1007/s00259-018-4188-8 false true Reference 37391816 /api/reference/37391816 18. Henriksen 2016: Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [18F]-fluoroethyltyrosine (FET) PET/MRI: Feasibility, agreement and initial experience., Eur. J. Pediatr., 43, p. 103 18 false true Reference 37391817 /api/reference/37391817 19. Kaiser, L., Holzgreve, A., Quach, S., Ingrisch, M., Unterrainer, M., Dekorsy, F.J., Lindner, S., Ruf, V., Brosch-Lenz, J., and Delker, A. (2021). Differential Spatial Distribution of TSPO or Amino Acid PET Signal and MRI Contrast Enhancement in Gliomas. Cancers, 14., DOI: 10.20944/preprints202111.0026.v1 19 10.20944/preprints202111.0026.v1 false true Reference 37391818 /api/reference/37391818 20. Unterrainer 2018: Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: A double-tracer pilot study., Eur. J. Nucl. Med., 46, p. 580, DOI: 10.1007/s00259-018-4166-1 20 10.1007/s00259-018-4166-1 false true Reference 37391819 /api/reference/37391819 21. Brown 2016: Association of the Extent of Resection with Survival in Glioblastoma: A systematic review and meta-analysis., JAMA Oncol., 2, p. 1460, DOI: 10.1001/jamaoncol.2016.1373 21 10.1001/jamaoncol.2016.1373 false true Reference 37391820 /api/reference/37391820 22. Guerrini, F., Roca, E., and Spena, G. (2022). Supramarginal Resection for Glioblastoma: It Is Time to Set Boundaries! A Critical Review on a Hot Topic. Brain Sci., 12., DOI: 10.3390/brainsci12050652 22 10.3390/brainsci12050652 false true Reference 37391821 /api/reference/37391821 23. Certo 2020: Supramarginal resection of glioblastoma: 5-ALA fluorescence, combined intraoperative strategies and correlation with survival., J. Neurosurg. Sci., 63, p. 625, DOI: 10.23736/S0390-5616.19.04787-8 23 10.23736/S0390-5616.19.04787-8 false true Reference 37391822 /api/reference/37391822 24. Certo 2020: FLAIRectomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series., Oper. Neurosurg., 20, p. 151, DOI: 10.1093/ons/opaa293 24 10.1093/ons/opaa293 false true Reference 37391823 /api/reference/37391823 25. Ort 2021: 18F-FET-PET-guided gross total resection improves overall survival in patients with WHO grade III/IV glioma: Moving towards a multimodal imaging-guided resection., J. Neuro-Oncology, 155, p. 71, DOI: 10.1007/s11060-021-03844-1 25 10.1007/s11060-021-03844-1 false true Reference 37391824 /api/reference/37391824 26. Rosen 2021: Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement., Sci. Rep., 11, p. 20828, DOI: 10.1038/s41598-021-00193-x 26 10.1038/s41598-021-00193-x false true Reference 37391825 /api/reference/37391825 27. Ceccon 2020: Early treatment response assessment using 18F-FET PET compared to contrast-enhanced MRI in glioma patients following adjuvant temozolomide chemotherapy., J. Nucl. Med., 62, p. 918, DOI: 10.2967/jnumed.120.254243 27 10.2967/jnumed.120.254243 false true Reference 37391826 /api/reference/37391826 28. Galldiks 2021: Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients—A report of the PET/RANO group., Neuro-Oncology, 23, p. 881, DOI: 10.1093/neuonc/noab013 28 10.1093/neuonc/noab013 false true Reference 37391827 /api/reference/37391827 29. Prather 2022: A systematic review of amino acid PET in assessing treatment response to temozolomide in glioma., Neuro-Oncology Adv., 4, p. vdac008, DOI: 10.1093/noajnl/vdac008 29 10.1093/noajnl/vdac008 false true Reference 37391828 /api/reference/37391828 30. Galldiks 2019: Comment on “Hypometabolic gliomas on FET-PET—Is there an inverted U-curve for survival?”., Neuro-Oncology, 21, p. 1612, DOI: 10.1093/neuonc/noz173 30 10.1093/neuonc/noz173 false true Reference 37391829 /api/reference/37391829 31. Galldiks 2019: Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: Clinical relevance in glioma patients., Neuro-Oncology, 21, p. 1331, DOI: 10.1093/neuonc/noz083 31 10.1093/neuonc/noz083 false true Reference 37391830 /api/reference/37391830 32. Kamson 2019: Hypometabolic gliomas on FET-PET—Is there an inverted U-curve for survival?., Neuro-Oncology, 21, p. 1221, DOI: 10.1093/neuonc/noz122 32 10.1093/neuonc/noz122 false true Reference 37391831 /api/reference/37391831 33. Chourmouzi 2014: Imaging of Brain Tumors., Surg. Oncol. Clin. North Am., 23, p. 629, DOI: 10.1016/j.soc.2014.07.004 33 10.1016/j.soc.2014.07.004 false true Reference 37391832 /api/reference/37391832 34. van de Weijer, T., Broen, M.P.G., Moonen, R.P.M., Hoeben, A., Anten, M., Hovinga, K., Compter, I., van der Pol, J.A.J., Mitea, C., and Lodewick, T.M. (2022). The Use of 18F-FET-PET-MRI in Neuro-Oncology: The Best of Both Worlds—A Narrative Review. Diagnostics, 12., DOI: 10.3390/diagnostics12051202 34 10.3390/diagnostics12051202 false true Reference 37391833 /api/reference/37391833 35. Cha 2004: Perfusion MR Imaging of Brain Tumors., Top. Magn. Reson. Imaging, 15, p. 279, DOI: 10.1097/00002142-200410000-00002 35 10.1097/00002142-200410000-00002 false true Reference 37391834 /api/reference/37391834 36. Lasocki 2019: Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research., Am. J. Neuroradiol., 40, p. 758, DOI: 10.3174/ajnr.A6025 36 10.3174/ajnr.A6025 false true Reference 37391835 /api/reference/37391835 37. Eichberg 2020: Incidence of high grade gliomas presenting as radiographically non-enhancing lesions: Experience in 111 surgically treated non-enhancing gliomas with tissue diagnosis., J. Neuro-Oncology, 147, p. 671, DOI: 10.1007/s11060-020-03474-z 37 10.1007/s11060-020-03474-z false true Reference 37391836 /api/reference/37391836 38. Gempt 2015: 18F-fluoro-ethyl-tyrosine positron emission tomography for grading and estimation of prognosis in patients with intracranial gliomas., Eur. J. Radiol., 84, p. 955, DOI: 10.1016/j.ejrad.2015.01.022 38 10.1016/j.ejrad.2015.01.022 false true Reference 37391837 /api/reference/37391837 39. Pichler 2010: Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance?., Eur. J. Nucl. Med., 37, p. 1521, DOI: 10.1007/s00259-010-1457-6 39 10.1007/s00259-010-1457-6 false true Reference 37391838 /api/reference/37391838 40. Rapp 2012: Diagnostic Performance of 18F-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of Glioma., J. Nucl. Med., 54, p. 229, DOI: 10.2967/jnumed.112.109603 40 10.2967/jnumed.112.109603 false true Reference 37391839 /api/reference/37391839 41. Jaber 2016: The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors., Neurosurgery, 78, p. 401, DOI: 10.1227/NEU.0000000000001020 41 10.1227/NEU.0000000000001020 false true Reference 37391840 /api/reference/37391840 42. Poulsen 2017: The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma., Eur. J. Nucl. Med. Mol. Imaging, 44, p. 373, DOI: 10.1007/s00259-016-3494-2 42 10.1007/s00259-016-3494-2 false true /api/publication/33564736 Nagy Dávid Gergő et al. Therapy Defining at Initial Diagnosis of Primary Brain Tumor—The Role of 18F-FET PET/CT and MRI. (2023) BIOMEDICINES 2227-9059 11 1<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10083677"><a href="/gui2/?type=authors&mode=browse&sel=10083677" target="_blank">Nagy Dávid Gergő (<span class="authorship-author-name">Nagy Dávid Gergő</span> <span class="authorAux-mtmt"> idegsebészet, neuroonkológia</span>) </a> </span> <span class="author-affil">Országos Mentális, Ideggyógyászati és Idegsebészeti Intézet; <span title="Országos Mentális, Ideggyógyászati és Idegsebészeti Intézet">OMIII</span>/Amerikai úti Ideggyógyászati és Idegsebészeti Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10045848"><a href="/gui2/?type=authors&mode=browse&sel=10045848" target="_blank">Fedorcsák Imre (<span class="authorship-author-name">Fedorcsák Imre</span> <span class="authorAux-mtmt"> idegsebészet</span>) </a> </span> <span class="author-affil">Országos Mentális, Ideggyógyászati és Idegsebészeti Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10026954"><a href="/gui2/?type=authors&mode=browse&sel=10026954" target="_blank">Bagó Attila György (<span class="authorship-author-name">Bagó Attila György</span> <span class="authorAux-mtmt"> Idegsebészet</span>) </a> </span> <span class="author-affil">Országos Mentális, Ideggyógyászati és Idegsebészeti Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10032350"><a href="/gui2/?type=authors&mode=browse&sel=10032350" target="_blank">Gáti Georgina (<span class="authorship-author-name">Gáti Georgina</span> <span class="authorAux-mtmt"> neurobiológia</span>) </a> </span> <span class="author-affil">Országos Mentális, Ideggyógyászati és Idegsebészeti Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10030006"><a href="/gui2/?type=authors&mode=browse&sel=10030006" target="_blank">Martos János (<span class="authorship-author-name">Martos János</span> <span class="authorAux-mtmt"> Radiológia, neuroradiológia</span>) </a> </span> <span class="author-affil">Országos Mentális, Ideggyógyászati és Idegsebészeti Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Szabó Péter </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10028430"><a href="/gui2/?type=authors&mode=browse&sel=10028430" target="_blank">Rajnai Hajnalka (<span class="authorship-author-name">Rajnai Hajnalka</span> <span class="authorAux-mtmt"> Patológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10017547"><a href="/gui2/?type=authors&mode=browse&sel=10017547" target="_blank">Kenessey István^** ✉ (<span class="authorship-author-name">Kenessey István</span> <span class="authorAux-mtmt"> Patológia, onkológia</span>) </a> </span> <span class="author-affil">Országos Onkológiai Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai, Igazságügyi és Biztosítási Orvostani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10002526"><a href="/gui2/?type=authors&mode=browse&sel=10002526" target="_blank">Borbély Katalin (<span class="authorship-author-name">Borbély Katalin</span> <span class="authorAux-mtmt"> Neurológia, nukleáris medicina</span>) </a> </span> <span class="author-affil">Országos Onkológiai Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;33564736" target="_blank">Therapy Defining at Initial Diagnosis of Primary Brain Tumor—The Role of 18F-FET PET/CT and MRI</a></div> <div> <span class="journal-title">BIOMEDICINES</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/2227-9059">2227-9059</a>)</span>: <span class="journal-volume">11</span> <span class="journal-issue">1</span> <span class="page"> Paper 128. 13 p. </span> <span class="year">(2023)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.3390/biomedicines11010128" target="_blank" href="https://doi.org/10.3390/biomedicines11010128"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000914427600001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000914427600001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85146705622" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85146705622"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="36672636" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36672636&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 6</span> | Független: 3 | Függő: 3 | Nem jelölt: 0 | WoS jelölt: 5 | Scopus jelölt:&nbsp;6 | WoS/Scopus jelölt:&nbsp;6 | DOI jelölt:&nbsp;5 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;33564736&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 4 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 33564736</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="lastModified">Utolsó módosítás: 2024.04.17. 10:09 Havas Petra (OMIII admin4) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: National Institute of Mental Health, Neurology and Neurosurgery, Budapest, 1145, Hungary Scanomed Ltd, Budapest, 1145, Hungary Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, 1085, Hungary National Cancer Registry, National Institute of Oncology, Budapest, 1122, Hungary ...</pre> </div></div>